| Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. | |
| | |
MedLine Citation:
|
PMID: 10334418 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: We sought to study the effect of early infusion of abciximab on coronary patency before primary angioplasty in patients with acute myocardial infarction. BACKGROUND: Glycoprotein IIb/IIIa antagonists have proved to be effective in reducing ischemic events associated with coronary angioplasty. The present study explores whether abciximab alone, without administration of thrombolytic therapy, may induce reperfusion in patients with acute myocardial infarction. METHODS: In the Glycoprotein Receptor Antagonist Patency Evaluation pilot study 60 patients with less than 6 h signs and symptoms of acute myocardial infarction eligible for primary angioplasty received in the emergency room a bolus of abciximab 250 microg/kg followed by a 12-h infusion of 10 microg/min. All patients were also treated with an oral dose of 160 mg aspirin and 5,000 IU of heparin intravenously. As soon as possible a diagnostic angiography was performed to evaluate the patency of the infarct-related artery. RESULTS: The median time between onset of symptoms and the administration of the abciximab bolus was 150 min (range 45 to 345), and the median time between abciximab bolus and first contrast injection in the infarct-related artery was 45 min (range 10 to 150). In 24 patients (40%, 95% confidence interval 28% to 52%) Thrombolysis in Myocardial Infarction (TIMI) flow grade 2 or 3 was observed at a median time of 45 min (range 10 to 150) after abciximab bolus; TIMI flow grade 3 was observed in 11 patients (18%, 95% confidence interval 9% to 28%). There was no difference in percentage of TIMI flow grade 2 or 3 between patients who received abciximab within 2.5 h after onset of symptoms or thereafter. CONCLUSIONS: Abciximab therapy given in the emergency room in patients awaiting primary angioplasty is associated with full reperfusion (TIMI flow grade 3) in about 20% and with TIMI flow grade 2 or 3 in about 40% of the patients at a median time of 45 min. These figures are higher than those in primary angioplasty trials without such pretreatment. Randomized controlled trials of very early infusion of abciximab, either prehospital or in-hospital, in patients eligible for angioplasty are warranted. |
| | |
Authors:
|
L F van den Merkhof; F Zijlstra; H Olsson; L Grip; G Veen; F W Bär; M J van den Brand; M L Simoons; F W Verheugt |
Related Documents
:
|
11385208 - Intracarotid abciximab injection to abort impending ischemic stroke during carotid angi... 2146328 - Parametric assessment of myocardial perfusion during interventional cardiac catheteriza... 2524268 - Acute reocclusion during percutaneous transluminal coronary angioplasty: immediate and ... 7722148 - Intracoronary irradiation markedly reduces neointimal proliferation after balloon angio... 15057438 - Direct stenting with taxus stents seems to be as safe and effective as with predilatati... 8329628 - Comparison of short-time fourier, wavelet and time-domain analyses of intracardiac sounds. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 33 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 1999 May |
Date Detail:
|
Created Date: 1999-06-03 Completed Date: 1999-06-03 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1528-32 Citation Subset: AIM; IM |
Affiliation:
|
Heartcenter, University Hospital, Nijmegen, The Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Angioplasty, Transluminal, Percutaneous Coronary* Antibodies, Monoclonal / administration & dosage*, adverse effects Aspirin / administration & dosage, adverse effects Coronary Circulation / drug effects Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination Female Heparin / administration & dosage, adverse effects Humans Immunoglobulin Fab Fragments / administration & dosage*, adverse effects Infusions, Intravenous Male Middle Aged Myocardial Infarction / therapy* Pilot Projects Platelet Aggregation Inhibitors / administration & dosage*, adverse effects Premedication |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; 143653-53-6/abciximab; 50-78-2/Aspirin; 9005-49-6/Heparin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prog...
Next Document: A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatali...